ATE500503T1 - Cd86- und cd80-rezeptorkonkurrenztests - Google Patents

Cd86- und cd80-rezeptorkonkurrenztests

Info

Publication number
ATE500503T1
ATE500503T1 AT07762432T AT07762432T ATE500503T1 AT E500503 T1 ATE500503 T1 AT E500503T1 AT 07762432 T AT07762432 T AT 07762432T AT 07762432 T AT07762432 T AT 07762432T AT E500503 T1 ATE500503 T1 AT E500503T1
Authority
AT
Austria
Prior art keywords
receptor competition
competition tests
receptor
tests
antibodies
Prior art date
Application number
AT07762432T
Other languages
English (en)
Inventor
Robert M Townsend
Francisco Leon
Catherine A Fleener
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE500503T1 publication Critical patent/ATE500503T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Sampling And Sample Adjustment (AREA)
AT07762432T 2006-01-24 2007-01-23 Cd86- und cd80-rezeptorkonkurrenztests ATE500503T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US76162406P 2006-01-24 2006-01-24
US83201206P 2006-07-20 2006-07-20
US11/656,206 US7510844B2 (en) 2006-01-24 2007-01-22 CD86 and CD80 receptor competition assays
PCT/US2007/060893 WO2007087521A2 (en) 2006-01-24 2007-01-23 Cd86 and cd80 receptor competition assays

Publications (1)

Publication Number Publication Date
ATE500503T1 true ATE500503T1 (de) 2011-03-15

Family

ID=38198012

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07762432T ATE500503T1 (de) 2006-01-24 2007-01-23 Cd86- und cd80-rezeptorkonkurrenztests

Country Status (6)

Country Link
US (3) US7510844B2 (de)
EP (1) EP1984736B1 (de)
AT (1) ATE500503T1 (de)
CA (1) CA2638799C (de)
DE (1) DE602007012836D1 (de)
WO (1) WO2007087521A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010009794A1 (en) * 2008-07-25 2010-01-28 Merck Patent Gmbh, Method of determination of receptor binding saturation effected by monoclonal antibodies
KR101918456B1 (ko) * 2015-12-15 2018-11-16 앱클론(주) Cd80 및 cd86에 특이적으로 결합하는 항체
US20180206726A1 (en) 2016-12-07 2018-07-26 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
RU2652885C1 (ru) * 2017-07-20 2018-05-03 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина " Минздрава России) Штамм гибридных культивируемых клеток животных mus musculus α - продуцент моноклональных антител, специфичных к раково-тестикулярному антигену человека GAGE
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2020106704A2 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2020140070A1 (en) * 2018-12-27 2020-07-02 Gigagen, Inc. Anti-b7-h4 binding proteins and methods of use thereof
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
JPH06509417A (ja) * 1991-07-16 1994-10-20 トランスメッド　バイオテック　インコーポレイテッド 多重検体の同時分析の方法と構成
US6084067A (en) 1993-07-26 2000-07-04 Dana-Farber Cancer Institute CTLA4/CD28 ligands and uses therefor
ID21676A (id) * 1996-11-08 1999-07-08 Idec Pharma Corp Identifikasi interaksi-interaksi ikatan yang khas antara antibodi-antibodi dan antigen-antigen pembantu rangsangan b7.1 dan b7.2 manusia tertentu
US7094874B2 (en) * 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
AR031699A1 (es) 2000-05-26 2003-10-01 Bristol Myers Squibb Co Molecula mutante de ctla4 soluble que se enlaza a cd80 y/o cd86, molecula de acido nucleico que la codifica, vector y sistema vector que comprende a esta ultima, celula huesped que lo posee, metodo para producir una proteina mutante y dicha proteina, uso de la molecula mutante para preparar un medic
US20040022787A1 (en) * 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US7312086B2 (en) * 2000-12-07 2007-12-25 Bristol-Myers Squibb Company Methods of diagnosing colon adenocarcinoma using the human g-protein coupled receptor hgprbmy23
DK1397153T3 (da) 2001-05-23 2008-05-26 Bristol Myers Squibb Co Fremgangsmåde til beskyttelse af allogent ö-celle-transplantat ved anvendelse af oplöselige CTLA4-mutantmolekyler

Also Published As

Publication number Publication date
US7510844B2 (en) 2009-03-31
EP1984736A2 (de) 2008-10-29
WO2007087521A3 (en) 2007-11-01
CA2638799A1 (en) 2007-08-02
US20070172895A1 (en) 2007-07-26
WO2007087521A2 (en) 2007-08-02
DE602007012836D1 (de) 2011-04-14
EP1984736B1 (de) 2011-03-02
US8378082B2 (en) 2013-02-19
CA2638799C (en) 2014-05-27
US8969531B2 (en) 2015-03-03
US20120077207A1 (en) 2012-03-29
US20130197202A1 (en) 2013-08-01

Similar Documents

Publication Publication Date Title
ATE500503T1 (de) Cd86- und cd80-rezeptorkonkurrenztests
ATE514755T1 (de) Fluoreszenzfarbstoffe zur verwendung bei der glukoseerfassung
WO2010065568A3 (en) METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95
ATE517192T1 (de) Verfahren zur isolierung von zellen
PH12016500658A1 (en) Human anti-alpha-synuclein autoantibodies
WO2007100506A3 (en) Mass tags for quantitative analyses
IL195470A0 (en) Antibodies as t cell receptor mimics, methods of production and uses thereof
IL179427A0 (en) Antibodies as t cell receptor mimics, methods of production and uses thereof
WO2011047087A3 (en) Protein detection via nanoreporters
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
WO2007084321A3 (en) Antibodies to ox-2/cd200 and uses thereof
MX345092B (es) Anticuerpos anti-tau humanos,.
MX2012004833A (es) Analisis para detectar anticuerpos especificos a anticuerpos anti-ige terapeuticos y su uso en anafilaxis.
EP2048501A4 (de) Gegen intaktes menschliches autotaxin spezifischer antikörper, verfahren zum sreening davon sowie verfahren und reagens zur untersuchung eines bösartigen lymphoms mittels autotaxin-tests
ATE504002T1 (de) Erkennung und vorhersage von frühgeburten
WO2007120766A3 (en) Erythropoietin receptor agonists
MX2010000680A (es) Materiales y metodos para selección de esperma sexual.
WO2008073895A3 (en) Methods and devices for testing saliva
WO2012082742A3 (en) Detecting cancer with anti-ccl25 and anti-ccr9 antibodies
MX2010000979A (es) Metodos y composiciones para tratar enfermedad autoinmune.
WO2009023331A3 (en) Antibodies and improved test sample handling methods for use in assays for myeloperoxidase
WO2006116319A3 (en) Reagents that bind ccx-ckr2
WO2009132251A3 (en) Methods and compositions comprising anti-idiotypic antibodies to anti-mmp-14 antibodies
WO2009126889A8 (en) Assays for detecting pregnancy-associated glycoproteins
WO2011159741A3 (en) Tetranor-pgem/pgam specific immunogens, antibodies, tracers, assay kits and methods for making same

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties